PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N)

PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse

(2018) Bingxin Zheng et al.   Journal of Hematology & Oncology

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

(2018) Seung Tae Kim et al.   NATURE MEDICINE

Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 Expression in Patients with Non-Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis

(2018) Marra Aghajani et al.   THYROID

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer

(2017) Reinhard Büttner et al.   JOURNAL OF CLINICAL ONCOLOGY

Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer

(2017) Thomas A Adams et al.   MODERN PATHOLOGY

A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1

(2017) Patricia Gaule et al.   JAMA Oncology

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

(2017) David L. Rimm et al.   JAMA Oncology

Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability

(2016) Changqing Ma et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma

(2016) Elizabeth D Thompson et al.   GUT

Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies

(2016) Woo Young Sun et al.   Journal of Translational Medicine

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

(2016) Kei Muro et al.   LANCET ONCOLOGY

Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection

(2015) Shohei Eto et al.   Gastric Cancer

Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer

(2015) Yi Qing et al.   Drug Design Development and Therapy

PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells

(2015) K. M. Mahoney et al.   Cancer Immunology Research

Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer

(2014) J. R. Brown et al.   CLINICAL CANCER RESEARCH

Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer

(2014) Jingying Hou et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer

(2014) Jin Won Kim et al.   Gastric Cancer

Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance

(2014) Yiting Geng et al.   International Journal of Clinical Oncology

The role of B7-H1 in gastric carcinoma: clinical significance and related mechanism

(2014) Dong Jiang et al.   MEDICAL ONCOLOGY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE